Evidence map›Paper›PMID 26377311›Full record

ArticleBMC microbiology2015

Potential mechanisms of attenuation for rifampicin-passaged strains of Flavobacterium psychrophilum.

Karol Gliniewicz, Mark Wildung, Lisa H Orfe, Gregory D Wiens, Kenneth D Cain, Kevin K Lahmers, Kevin R Snekvik, Douglas R Call

Open access · goldAbstract read
In one paragraph

Article in BMC microbiology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.2field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Dual RNA-Seq ofPathogens (Basel, Switzerland) · 2023
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Karol GliniewiczDepartment of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, USA. karol@uidaho.edu.
Mark WildungMolecular Biology and Genomics Core, Washington State University, Pullman, WA, USA. wildung@wsu.edu.
Lisa H OrfePaul G. Allen School for Global Animal Health, Washington State University, Pullman, WA, USA. lorfe@vetmed.wsu.edu.
Gregory D WiensUSDA-ARS-National Center for Cool and Cold Water Aquaculture, Leetown, WV, USA. greg.wiens@ars.usda.gov.
Kenneth D CainDepartment of Fish and Wildlife Resources, University of Idaho, Moscow, ID, USA. kcain@uidaho.edu.
Kevin K LahmersDepartment of Biomedical Sciences and Pathobiology, Virginia Polytechnic Institute and State University, Blacksburg, VA, USA. klahmers@vt.edu.
Kevin R SnekvikDepartment of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, USA. ksnek@wsu.edu.
Douglas R CallDepartment of Veterinary Microbiology and Pathology, Washington State University, Pullman, WA, USA. drcall@wsu.edu.
Washington State University · USNational Center for Cool and Cold Water Aquaculture · USUniversity of Idaho · USVirginia Tech · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFlavobacterium psychrophilum is the etiologic agent of bacterial coldwater disease in salmonids. Earlier research showed that a rifampicin-passaged strain of F. psychrophilum (CSF 259-93B.17) caused no disease in rainbow trout (Oncorhynchus mykiss, Walbaum) while inducing a protective immune response against challenge with the virulent CSF 259-93 strain. We hypothesized that rifampicin passage leads to an accumulation of genomic mutations that, by chance, reduce virulence. To assess the pattern of phenotypic and genotypic changes associated with passage, we examined proteomic, LPS and single-nucleotide polymorphism (SNP) differences for two F. psychrophilum strains (CSF 259-93 and THC 02-90) that were passaged with and without rifampicin selection.

resultsRifampicin resistance was conveyed by expected mutations in rpoB, although affecting different DNA bases depending on the strain. One rifampicin-passaged CSF 259-93 strain (CR) was attenuated (4 % mortality) in challenged fish, but only accumulated eight nonsynonymous SNPs compared to the parent strain. A CSF 259-93 strain passaged without rifampicin (CN) accumulated five nonsynonymous SNPs and was partially attenuated (28 % mortality) compared to the parent strain (54.5 % mortality). In contrast, there were no significant change in fish mortalities among THC 02-90 wild-type and passaged strains, despite numerous SNPs accumulated during passage with (n = 174) and without rifampicin (n = 126). While only three missense SNPs were associated with attenuation, a Ser492Phe rpoB mutation in the CR strain may contribute to further attenuation. All strains except CR retained a gliding motility phenotype. Few proteomic differences were observed by 2D SDS-PAGE and there were no apparent changes in LPS between strains. Comparative methylome analysis of two strains (CR and TR) identified no shared methylation motifs for these two strains.

conclusionMultiple genomic changes arose during passage experiments with rifampicin selection pressure. Consistent with our hypothesis, unique strain-specific mutations were detected for the fully attenuated (CR), partially attenuated (CN) and another fully attenuated strain (B17).

Indexed as

Drug Resistance, BacterialAnimalsAnti-Bacterial AgentsDNA-Directed RNA PolymerasesFish DiseasesFlavobacteriaceae InfectionsFlavobacteriumLipopolysaccharidesMolecular Sequence DataOncorhynchus mykissPolymorphism, Single NucleotideProteomeRifampinSelection, GeneticSequence Analysis, DNASerial PassageAnti-Bacterial AgentsDNA-Directed RNA PolymerasesLipopolysaccharidesProteomeRifampinRNA polymerase beta subunit

Identifiers

PMID26377311
PMCPMC4571129
OpenAlexW2147806507

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.